Project Grant R01AR084797

Award Date 5/29/25
Completion Date 4/30/28
Dollars Obligated $1
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,643,228 Cooperative Agreement grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Worcester Polytechnic Institute (WPI) to develop an Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment (IMPACT). The key objectives of this 2-year IMPACT project are to: 1) Initiate a clinical trial of Mindfulness-Based Stress Reduction (MBSR) for chronic low back pain...
This $145,748 Project Grant from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) supports research aimed at addressing the underutilization of pain psychology treatment among socioeconomically disadvantaged individuals with chronic low back pain. The principal investigator, Dr. Fenan Rassu of Johns Hopkins University, will conduct a three-part study to: 1) investigate the impact of socioeconomic status on pain...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $305,909 to Goalistics LLC to develop a psychologist/nurse practitioner-guided, telehealth-delivered version of the Chronic Pain Management Program (CPMP). The key products and services to be delivered include: Development of training materials to certify licensed clinical/counseling psychologists and nurse practitioners...
This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), establishes an interdisciplinary clinical pain research training program at Mass General Brigham (MGB) in Boston. The $242,061 grant supports an intensive 2-3 year program that will train a diverse pool of postdoctoral fellows in conducting cutting-edge clinical pain research. Key focus areas include advancing health equity in...
This federal Project Grant award of $366,975.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to validate a translational rat model of chronic discogenic low back pain. The primary objectives are to: 1) Reproduce and validate a recently published rat model of disc degeneration-induced low back pain in an independent laboratory, and 2) Conduct further studies to establish the model's face,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The $774,930 award to the Regents of the University of Minnesota will be used over a 2-year (R61) and 1-year (R33) period to optimize the model to reproduce the behavioral, radiographic, and cellular/molecular features of...
The National Center for Complementary and Integrative Health (NCCIH) awarded a $817,330 Project Grant (CFDA 93.213 - Research and Training in Complementary and Integrative Health) to the University of Virginia to investigate an adaptive intervention to improve pain outcomes in patients with comorbid chronic low back pain and insomnia. The project will first enroll 300 patients in a cognitive behavioral therapy for insomnia (CBTI) program, then randomize non-responders to receive either a...
This $14.2 million project grant from the National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, will fund research from September 2022 to August 2025 under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The Massachusetts General Hospital will investigate the mechanisms by which spinal cord stimulation reduces pain, with the goal of improving device design and patient selection. Researchers will apply specialized nerve...
This $351,097 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the CFDA 93.279 Drug Use and Addiction Research Programs, funds the Mass General Brigham Interdisciplinary Clinical Pain Research Training Program. The program will support 8-10 postdoctoral fellows over 5 years, providing them with protected research time, mentorship, coursework, and training in 8 priority areas of clinical pain research. The goal is to expand the pool of...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $146,922 to evaluate the association between general chronic pain liability and clinically recognized substance use disorders. The research aims to clarify the relationship between chronic pain and substance use disorders, accounting for the heterogeneity across and comorbidity among chronic pain conditions, as well as potential shared...

INVESTIGATING MECHANISMS OF INTRA- AND INTER-INDIVIDUAL PAIN VARIABILITY IN PATIENTS WITH COMORBID CHRONIC PAIN AND DEPRESSION - PROJECT SUMMARY/ ABSTRACT CHRONIC LOW BACK PAIN (CLBP) IS THE MOST COMMON MUSCULOSKELETAL PAIN CONDITION ASSOCIATED WITH SUBSTANTIAL INTER-INDIVIDUAL VARIABILITY. FURTHER, MAJOR DEPRESSIVE DISORDER (MDD) IS COMORBID IN UP TO 46% OF INDIVIDUALS WITH CLBP, WHICH IS RELATED TO WORSE PAIN AND DEPRESSION SEVERITY, DISABILITY, AND QUALITY OF LIFE, AND POORER RESPONSE TO EXISTING TREATMENTS COMPARED TO CLBP ALONE. MDD IS ITSELF A HETEROGENOUS CONDITION, AND THUS ANY ASSOCIATION WITH CLBP ALSO LIKELY VARIES BETWEEN INDIVIDUALS. WHILE THE BIOPSYCHOSOCIAL MODEL HAS BEEN HELPFUL FOR IDENTIFYING BIOLOGICAL, PSYCHOLOGICAL, AND SOCIAL PROCESSES ASSOCIATED WITH CLBP, AS WELL AS HELPING TO EXPLAIN THE OVERLAP BETWEEN CLBP AND MDD, A MAJOR CHALLENGE IN OPTIMIZING THE TREATMENT IS IDENTIFYING WHICH FACTORS, AND IN WHICH COMBINATION, ARE MOST RELATED TO AN INDIVIDUAL'S UNIQUE PAIN EXPERIENCE. IN RESPONSE TO THE NOTICE OF FUNDING OPPORTUNITY FOR UNDERSTANDING INDIVIDUAL DIFFERENCES IN HUMAN PAIN CONDITIONS, THE PROPOSED RESEARCH WILL GENERATE INDIVIDUALIZED PREDICTION MODELS OF MOMENTARY PAIN INTENSITY AMONG 150 ADULTS WITH CLBP+MDD (AIM 1). THIS WILL BE ACCOMPLISHED BY A COMBINATION OF ECOLOGICAL MOMENTARY ASSESSMENTS (EMA) AND WHOLE-HEALTH METRICS OBTAINED FROM WEARABLES, ALL PROCESSED WITH A ROBUST MACHINE LEARNING (ML) PIPELINE PREVIOUSLY VALIDATED IN OUR LABORATORY. WE HYPOTHESIZE THAT PERSONALIZED PREDICTION MODELS OF PAIN VARIABILITY USING ML ALGORITHMS WILL BE FEASIBLE IN AT LEAST 80% OF PARTICIPANTS, ACHIEVING ~80% PREDICTION ACCURACY. AFTER OBTAINING INDIVIDUALIZED MODELS ON THE STUDY SAMPLE, WE WELL THEN APPLY DATA-DRIVEN CLUSTERING ALGORITHMS TO IDENTIFY SUBGROUPS OF PARTICIPANTS THAT SHARE TOP FEATURES OF INDIVIDUAL PAIN VARIABILITY (AIM 2A) AND RELATE THESE CLUSTERS TO UNDERLYING BIOLOGICAL MECHANISMS IMPLICATED IN CLBP+MDD (EMOTION BIAS AND REWARD PROCESSING WITH CONCURRENT EEG AND LABORATORY MEASURES OF CENTRAL SENSITIZATION) (AIM 2B). WE HYPOTHESIZE THAT UNIQUE PHENOTYPES WILL EMERGE CHARACTERIZED BY SHARED FEATURES OF INDIVIDUAL PAIN VARIABILITY AND THAT EMPIRICALLY-DERIVED PHENOTYPES WILL BE RELATED TO DISTINCT BIOLOGICAL MECHANISMS. THIS APPLICATION HOLDS PROMISE TO MAKE A MAJOR CONTRIBUTION TO THE SCIENTIFIC KNOWLEDGE OF BOTH INTRA- AND INTER-INDIVIDUAL PAIN VARIABILITY IN PERSONS WITH CLBP+MDD. THIS APPROACH REPRESENTS A SHIFT IN CURRENT RESEARCH PRACTICES, WHICH HAS LARGELY FOCUSED ON ANALYSIS AT THE GROUP LEVEL, BY TAKING A DATA-DRIVEN APPROACH TO ELUCIDATE INDIVIDUAL DIFFERENCES IN CLBP+MDD. FURTHER, OUR CLUSTERING APPROACH IN AIM 2 IS HIGHLY NOVEL, WHICH GROUPS INDIVIDUALS BASED ON TOP FEATURES OF INDIVIDUAL PAIN VARIABILITY, ENABLING A HIGH PRECISION METHOD OF IDENTIFYING HOMOGENOUS SUBGROUPS AND EXAMINING PUTATIVE UNDERLYING MECHANISMS OF CLBP+MDD SUBTYPES.

Posted 5/29/25, 12:00 AM